Technology Prognosis

tracking technologies before you have to make a decision

Prognosis is a horizon scanning service that monitors emerging health technologies as they go through clinical trial development and the regulatory approval process.

View a sampling of our Prognosis reports.

Zulresso (Brexanolone) for Postpartum Depression

June 27, 2019 Technology Prognosis

Zulresso (brexanolone) is a sterile solution of allopregnanolone for intravenous infusion in development for the treatment of postpartum depression (PPD). Allopregnanolone is a positive allosteric modulator of the neurotransmitter gamma-aminobutyric acid (GABAA) receptors. Plasma allopregnanolone concentrations rise in concert with progesterone throughout pregnancy, reaching the highest physiological concentrations in the third trimester. After childbirth, these concentrations decrease abruptly. Failure of GABAA receptors to adapt to these changes may have a role in triggering PPD. Although the cause of PPD is not entirely understood, it is proposed that treatment of women with PPD with doses of allopregnanolone that result in serum...

Luspatercept for Beta-Thalassemia

June 26, 2019 Technology Prognosis

Luspatercept is an erythroid maturation agent administered via subcutaneous injection being developed for the treatment of patients with transfusion-dependent beta-thalassemia. This recombinant fusion protein is believed to help immature cells develop into red blood cells, thereby preventing anemia and reducing or eliminating the need for frequent blood transfusions.

Celiprolol (Proposed Name: Edsivo) for Vascular Ehlers-Danlos Syndrome

June 26, 2019 Technology Prognosis

Celiprolol is an oral beta-1 adrenoceptor antagonist with partial beta-2 agonist activity proposed for the prevention of complications of vascular Ehlers-Danlos syndrome (EDS). Celiprolol has antihypertensive and antianginal properties, in addition to influencing vascular tone and smooth muscle. Celiprolol is believed to provide clinical benefit for people with vascular EDS by promoting normal collagen synthesis in the blood vessels, and by shifting the pressure load away from the vessels most prone to dissection and rupture.

Sunosi (Solriamfetol)

June 25, 2019 Technology Prognosis

Sunosi (solriamfetol) is an oral selective dopamine and norepinephrine reuptake inhibitor indicated for the treatment of excessive sleepiness in adult patients with narcolepsy or obstructive sleep apnea.

Polivy (Polatuzumab Vedotin-piiq) for Diffuse Large B-Cell Lymphoma

June 12, 2019 Technology Prognosis

Polivy (polituzumab-vedotin-piiq) is an intravenously administered CD79b-directed antibody-drug conjugate indicated in combination with a rituximab product and bendamustine for adult patients with relapsed/refractory diffuse large B-cell lymphoma after at least 2 prior therapies.